[1]洪玲丽.氯沙坦钾与依那普利治疗高血压合并高尿酸血症的疗效比较[J].医学信息,2023,36(20):133-136.[doi:10.3969/j.issn.1006-1959.2023.20.026]
　HONG Ling-li.Efficacy Comparison of Losartan Potassium and Enalapril in the Treatment of Hypertension Complicated with Hyperuricemia[J].Journal of Medical Information,2023,36(20):133-136.[doi:10.3969/j.issn.1006-1959.2023.20.026]
点击复制

氯沙坦钾与依那普利治疗高血压合并高尿酸血症的疗效比较()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年20期
页码:
133-136
栏目:
论著
出版日期:
2023-10-15

文章信息/Info

Title:
Efficacy Comparison of Losartan Potassium and Enalapril in the Treatment of Hypertension Complicated with Hyperuricemia
文章编号:
1006-1959（2023）20-0133-04
作者:
洪玲丽
（金溪县中医院药剂科，江西 金溪 344800）
Author(s):
HONG Ling-li
(Pharmacy Department of Jinxi County Hospital of Traditional Chinese Medicine,Jinxi 344800,Jiangxi,China)
关键词:
高血压; 高尿酸血症; 氯沙坦钾; 依那普利; 收缩压; 舒张压; 血尿酸
Keywords:
Hypertension; Hyperuricemia; Losartan potassium; Enalapril; Systolic blood pressure; Diastolic blood pressure; Blood uric acid
分类号:
R544.1；R589
DOI:
10.3969/j.issn.1006-1959.2023.20.026
文献标志码:
A
摘要:
目的 比较氯沙坦钾与依那普利治疗高血压合并高尿酸血症（HUA）的临床疗效。方法 选取2020年7月-2022年7月金溪县中医院收治的80例高血压并HUA患者，按照随机数字表法分为氯沙坦钾组（40例）与依那普利组（40例），氯沙坦钾组给予氯沙坦钾治疗，依那普利组采用依那普利治疗，比较两组降压疗效、降尿酸疗效、血压水平[收缩压（SBP）、舒张压（DBP）]、血尿酸、炎症因子水平[白介素6（IL-6）、肿瘤坏死因子（TNF-α)]及不良反应。结果 两组降压总有效率比较，差异无统计学意义（P＞0.05）；氯沙坦钾组的降尿酸有效率高于依那普利组（P＜0.05）；两组治疗后SBP、DBP、血尿酸水平均低于治疗前，且氯沙坦钾组血尿酸水平低于依那普利组（P＜0.05），但两组SBP、DBP水平比较，差异无统计学意义（P＞0.05）；两组治疗后IL-6、TNF-α水平低于治疗前，且氯沙坦钾组IL-6、TNF-α水平低于依那普利组（P＜0.05）；氯沙坦钾组与依那普利组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 氯沙坦钾与依那普利在高血压并HUA治疗中均具有确切疗效，二者降压效果相当，且不良反应相似，但氯沙坦钾的降尿酸作用更优，可促进患者炎症因子水平的进一步下调。
Abstract:
Objective To compare the clinical efficacy of losartan potassium and enalapril in the treatment of hypertension complicated with hyperuricemia (HUA).Methods A total of 80 patients with hypertension complicated with HUA admitted to Jinxi County Hospital of Traditional Chinese Medicine from July 2020 to July 2022 were selected and divided into losartan potassium group (40 patients) and enalapril group (40 patients) according to the random number table method. The losartan potassium group was treated with losartan potassium, and the enalapril group was treated with enalapril. The antihypertensive effect, uric acid reduction effect, blood pressure level [systolic blood pressure (SBP), diastolic blood pressure (DBP)], serum uric acid, inflammatory factor levels [interleukin 6 (IL-6), tumor necrosis factor (TNF-α)] and adverse reactions were compared between the two groups.Results There was no significant difference in the total effective rate of blood pressure reduction between the two groups (P>0.05). The total effective rate of lowering uric acid in losartan potassium group was higher than that in enalapril group (P<0.05). After treatment, the levels of SBP, DBP and serum uric acid in the two groups were lower than those before treatment, and the level of serum uric acid in the losartan potassium group was lower than that in the enalapril group (P<0.05), but there was no significant difference in the levels of SBP and DBP between the two groups (P>0.05). After treatment, the levels of IL-6 and TNF-α in the two groups were lower than those before treatment, and the levels of IL-6 and TNF-α in the losartan potassium group were lower than those in the enalapril group (P<0.05). There was no significant difference in the incidence of adverse reactions between losartan potassium group and enalapril group (P>0.05).Conclusion Losartan potassium and enalapril have definite curative effects in the treatment of hypertension complicated with HUA. The antihypertensive effects of the two are similar, and the adverse reactions are similar. However, losartan potassium has a better effect on reducing uric acid, which can promote the further down-regulation of inflammatory factors in patients.

参考文献/References:

[1]陈剑锋,马斌.老年体检人群高尿酸血症流行现况及影响因素分析研究[J].中国全科医学,2020,23(5):604-610.[2]唐庆业,刘文举,陈世雄,等.痛风定胶囊辅助氯沙坦在老年高血压伴高尿酸血症中应用及对血清PICP、CITP和sICAM-1水平的影响[J].中国老年学杂志,2022,42(2):257-260.[3]黄海玲,吴婷婷,钟家玲.控制尿酸对合并高尿酸血症的老年高血压病人血压的影响[J].实用老年医学,2018,32(11):1027-1030.[4]刘亚南,胡莹莹,张海燕,等.盐酸特拉唑嗪片联合氯沙坦钾对高血压患者的治疗效果及对氧化应激反应的影响[J].中国医药,2020,15(6):859-863.[5]黄周明,施发丽.氯沙坦钾片与氯沙坦氢氯噻嗪片的降压疗效对比及对高尿酸血症的影响[J].山西医药杂志,2019,48(14):1667-1669.[6]冯仕银,陈卓,蔡林芮,等.氯沙坦钾片在中国健康志愿者中的药动学及生物等效性试验[J].中国新药杂志,2019,28(10):1208-1213.[7]袁锐,张润峰,兰莉.依那普利叶酸片联合辛伐他汀对H型高血压患者炎症因子的影响[J].临床和实验医学杂志,2018,17(14):1532-1535.[8]陈慧,徐群威.依那普利联用叶酸治疗H型高血压的临床疗效及对血管内皮功能的影响[J].中华全科医学,2017,15(5):805-807,867.[9]高血压联盟(中国),中国医疗保健国际交流促进会高血压分会,中国高血压防治指南修订委员会,等.中国高血压防治指南(2018年修订版)[J].中国心血管杂志,2019,24(1):24-56.[10]中华医学会内分泌学分会.中国高尿酸血症与痛风诊疗指南(2019)[J].中华内分泌代谢杂志,2020,36(1):1-13.[11]朱冰坡,范利,蔺士杰,等.益阳地区老年体检人群高尿酸血症患病率及相关危险因素分析[J].中华老年心脑血管病杂志,2018,20(2):164-167.[12]汤瑜昳,杨德辉,易定锋.阿利沙坦酯和缬沙坦治疗高血压病合并高尿酸血症效果比较[J].湖南师范大学学报(医学版),2020,17(1):40-42.[13]牟斌,陈梦诗,钟尔专.马来酸依那普利联合叶酸治疗H型高血压疗效观察[J].海南医学,2018,29(12):1739-1741.[14]孙晓伟.药物联合治疗老年糖尿病高血压合并高尿酸血症的临床效果观察[J].实用临床医药杂志,2018,22(1):133-135.[15]刘刚.氯沙坦钾对老年原发性高血压伴高尿酸血症的临床疗效及安全性评价[J].川北医学院学报,2017,32(5):791-793.[16]洪雁,赵梅.氯沙坦钾与坎地沙坦酯对原发性高血压伴高尿酸血症患者的临床疗效及内皮祖细胞的修复作用的对比分析[J].广西医科大学学报,2017,34(11):1621-1623.[17]杜海霞.缬沙坦与依那普利对高血压患者QT间期离散度与室性早搏的疗效[J].心血管康复医学杂志,2017,26(3):295-299.[18]李钰艳,吴艳,喻荷淋,等.依那普利联合苯磺酸氨氯地平对糖尿病肾病伴高血压患者血清炎性因子及肾功能的影响[J]. 疑难病杂志,2021,20(8):761-764.[19]吴立华,姜阳,苏豪,等.氯沙坦对高血压合并高尿酸血症病人血尿酸的影响[J].中西医结合心脑血管病杂志,2017,15(14):1758-1760.[20]缐海英,刘小娟.氨氯地平联合氯沙坦钾治疗高血压合并高尿酸血症血尿酸、尿微量蛋白及动脉硬化指数的分析[J].中西医结合心脑血管病杂志,2020,18(15):2495-2497.[21]张平,王立中,马乔岩,等.依那普利叶酸对中青年H型高血压血清炎症因子和内皮素的影响与心血管疾病的关系[J].中国循证心血管医学杂志,2022,14(3):301-304.[22]林绮芬,于斌,苏大理,等.氯沙坦和替米沙坦治疗高血压伴高尿酸血症临床效果差异分析[J].贵州医药,2019,43(2):271-274.

相似文献/References:

[1]颜 明,龚丽娜,王淑清.彩超在高血压患者肾动脉血流动力学检测中的应用分析[J].医学信息,2018,31(02):156.[doi:10.3969/j.issn.1006-1959.2018.02.060]
　YAN Ming,GONG Li-na,WANG Shu-qing.Application of Color Doppler Ultrasound in the Measurement of Renal Artery Hemodynamics in Patients with Hypertension[J].Journal of Medical Information,2018,31(20):156.[doi:10.3969/j.issn.1006-1959.2018.02.060]
[2]夏能能,任 薇,杜建平,等.1953~2016年中医药治疗高血压领域研究热点分析[J].医学信息,2018,31(04):18.[doi:10.3969/j.issn.1006-1959.2018.04.007]
　XIA Neng-neng,REN Wei,DU Jian-ping,et al.Analysis of Hot Spots in the Research of Traditional Chinese Medicine in Treating Hypertension from 1953 to 2016[J].Journal of Medical Information,2018,31(20):18.[doi:10.3969/j.issn.1006-1959.2018.04.007]
[3]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,31(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
　JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Journal of Medical Information,2018,31(20):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[4]孙 秋,万 明,冯会芳,等.高尿酸血症生化血常规特征分析[J].医学信息,2018,31(06):153.[doi:10.3969/j.issn.1006-1959.2018.06.054]
　SUN Qiu,WAN Ming,FENG Hui-fang,et al.Analysis of Biochemical Blood Routine Characteristics of Hyperuricemia[J].Journal of Medical Information,2018,31(20):153.[doi:10.3969/j.issn.1006-1959.2018.06.054]
[5]乔 君,高 翔,王 瑜,等.缬沙坦对原发性高血压患者外周PBMC中IL-17表达的影响[J].医学信息,2018,31(07):65.[doi:10.3969/j.issn.1006-1959.2018.07.021]
　QIAO Jun,GAO Xiang,WANG Yu,et al.The Effect of Valsartan on the Expression of IL-17 in Peripheral PBMC of Patients with Essential Hypertension[J].Journal of Medical Information,2018,31(20):65.[doi:10.3969/j.issn.1006-1959.2018.07.021]
[6]董巧玲.健康教育对原发性高血压患者治疗效果的影响[J].医学信息,2018,31(09):180.[doi:10.3969/j.issn.1006-1959.2018.09.060]
　DONG Qiao-ling.Effect of Health Education on Treatment of Patients with Essential Hypertension[J].Journal of Medical Information,2018,31(20):180.[doi:10.3969/j.issn.1006-1959.2018.09.060]
[7]俞 瑞,吴建荣,杨晓萍,等.健康体检者中高尿酸人群血脂水平变化及 甘油三脂升高的相关因素分析[J].医学信息,2018,31(13):62.[doi:10.3969/j.issn.1006-1959.2018.13.018]
　YU Rui,WU Jian-rong,YANG Xiao-ping,et al.Analysis of Related Factors of Blood Lipid Levels and Elevated Triglycerides in Hyperuricemia Population in Healthy Subjects[J].Journal of Medical Information,2018,31(20):62.[doi:10.3969/j.issn.1006-1959.2018.13.018]
[8]张 铭,徐 蔷,肖 帆,等.芹菜籽提取物对高尿酸血症模型大鼠的血尿酸以及 抗氧化能力的影响[J].医学信息,2018,31(13):84.[doi:10.3969/j.issn.1006-1959.2018.13.024]
　ZHANG Ming,XU Qiang,XIAO Fan,et al.Effects of Celery Seed Extract on Serum Uric Acid and Antioxidant Capacity of Hyperuricemia Rats[J].Journal of Medical Information,2018,31(20):84.[doi:10.3969/j.issn.1006-1959.2018.13.024]
[9]沈 正,王庆海.焦虑抑郁障碍与血压变异性研究[J].医学信息,2018,31(16):34.[doi:10.3969/j.issn.1006-1959.2018.16.010]
　SHEN Zheng,WANG Qing-hai.Study on Anxiety and Depression Disorder and Blood Pressure Variability[J].Journal of Medical Information,2018,31(20):34.[doi:10.3969/j.issn.1006-1959.2018.16.010]
[10]左洪亮.苯磺酸左旋氨氯地平片治疗中老年患者 轻中度原发性高血压的疗效观察[J].医学信息,2018,31(16):120.[doi:10.3969/j.issn.1006-1959.2018.16.037]
　ZUO Hong-liang.Efficacy of Levamlodipine Besylate Tablets in Treatment of Mild to Moderate Essential Hypertension in Middle-aged and Elderly Patients[J].Journal of Medical Information,2018,31(20):120.[doi:10.3969/j.issn.1006-1959.2018.16.037]
[11]胡端凤,罗正辉,李清芳.尿毒清颗粒联合非布司他片治疗高血压肾病合并高尿酸血症的临床研究[J].医学信息,2021,34(23):62.[doi:10.3969/j.issn.1006-1959.2021.23.017]
　HU Duan-feng,LUO Zheng-hui,LI Qing-fang.Clinical Study on Niaoduqing Granules Combined with Febuxostat Tablets in Treatment of Hypertensive Nephropathy Complicated with Hyperuricemia[J].Journal of Medical Information,2021,34(20):62.[doi:10.3969/j.issn.1006-1959.2021.23.017]
[12]胡丽平,蔡 华,唐 璐,等.地中海饮食对代谢相关性疾病作用的研究进展[J].医学信息,2023,36(22):183.[doi:10.3969/j.issn.1006-1959.2023.22.043]
　HU Li-ping,CAI Hua,TANG Lu,et al.Research Progress on the Effect of Mediterranean Diet on Metabolic-related Diseases[J].Journal of Medical Information,2023,36(20):183.[doi:10.3969/j.issn.1006-1959.2023.22.043]
[13]姚 灵,木拉力别克·黑扎提,杨文博,等.高血压合并阻塞性睡眠呼吸暂停患者肾素-血管紧张素-醛固酮系统与高尿酸血症的相关性分析[J].医学信息,2024,37(14):85.[doi:10.3969/j.issn.1006-1959.2024.14.016]
　YAO Ling,HEIZHATI·Mulalibieke,YANG Wen-bo,et al.Correlation Analysis Between Renin-angiotensin-aldosterone System and Hyperuricemia in Patients with Hypertension Complicated with Obstructive Sleep Apnea[J].Journal of Medical Information,2024,37(20):85.[doi:10.3969/j.issn.1006-1959.2024.14.016]

更新日期/Last Update: 1900-01-01